Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Stock Climbs 29 Percent on Strong Q2 Revenue Growth, Profit

NEW YORK (GenomeWeb News) - Shares in Illumina were up more than 29 percent, or $8.42, at $37.28 in mid-afternoon trading after the company reported strong second-quarter earnings.
 
As GenomeWeb News reported this morning, Illumina reported a 163-percent surge in second-quarter revenues and swung into profitability from a loss in the second quarter of 2005.
 
Separately today, research firm Global Crown Capital upgraded Illumina's stock to "Overweight" from "Neutral."

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.